Search Results for: "Clinic Roundup"
-
Pharma: Clinic Roundup
Pfizer Inc., of New York, began a Phase I trial of PF-06410293 (adalimumab), its biosimilar version of Humira -
Clinic Roundup
The company also reported pharmacokinetic data at NLA showing no drug-drug interaction between Vascepa and cholesterol drug Lipitor (atorvastatin, Pfizer Inc.) or anticoagulant warfarin -
Clinic Roundup
In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies -
Pharma: Clinic Roundup
Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, showing that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliqus (apixaban) compared to warfarin were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation -
Clinic Roundup
The randomized, double-blind, parallel group trial is evaluating TC-1734 against donepezil (Aricept, Pfizer Inc.) in approximately 300 patients at sites predominantly in Eastern Europe and the U.S. The Alzheimer's Disease Assessment Scale-cognitive subscale and the Clinician Interview-Based Impression of Change Plus Caregiver Input, or CIBIC-(+), are co-primary endpoints, with the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory replacing CIBIC-(+) as a co-primary -
Pharma: Clinic Roundup
Pfizer Inc., of New York, said that top-line data for a Phase IV trial of Celebrex (celecoxib) capsules or naproxen in juvenile idiopathic arthritis patients demonstrated no difference in changes to systolic blood pressure, the primary endpoint, and diastolic blood pressure, the secondary endpoint -
Clinic Roundup
GlycoMimetics partnered GMI-1070, a synthetic glycomimetic molecule designed to inhibit all three selectin types, in a worldwide agreement with Pfizer Inc., of New York, in 2011. (See BioWorld Today, Oct. 12, 2011 -
Clinic Roundup
Patients were randomized to 200 mg of tedizolid once a day for six days plus four days of placebo or 600 mg of linezolid (Zyvox, Pfizer Inc.) twice a day for 10 days -
Clinic Roundup
The randomized, international double-blind, multiple-crossover trial was designed to assess safety and efficacy in reducing the frequency of urination and incontinence episodes per day, compared to both placebo and active-control Detrol (tolterodine, Pfizer Inc -
Pharma: Clinic Roundup
Pfizer Inc., of New York, said the REMINDER trial of Inspra (eplerenone) showed statistically significant risk reductions in the primary composite efficacy endpoint, defined as time to first event of cardiovascular mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure (HF), sustained ventricular tachycardia or fibrillation, ejection fraction (EF) BioWorld Today | Tuesday, March 12, 2013
Pharma: Clinic Roundup
Pfizer Inc., of New York, said results from a Phase III study demonstrated immunogenicity, tolerability and safety of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) in adults infected with HIV
Pharma: Clinic Roundup
Pfizer Inc., of New York, said top-line results from a Phase III study showed Lyrica (pregabalin) capsules CV were as effective as levetiracetam (Keppra, UCB SA) as adjunctive therapy for refractory partial onset seizures in adults with epilepsy
Clinic Roundup
Acceleron Pharma Inc., of Cambridge, Mass., said it started a Phase II study testing dalantercept (ACE-041), an angiogenesis inhibitor designed to target the activin receptor-like kinase pathway, in combination with Inlyta (axitinib, Pfizer Inc.), a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma
Clinic Roundup
Cytos Biotechnology Ltd., of Zurich, Switzerland, said Pfizer Inc., of New York, dosed the first patient in a Phase I trial of Pfizer's anti-IgE vaccine, which is being developed using Cytos' virus-like-particle (VLP) vaccine platform
Pharma: Clinic Roundup
Pfizer Inc., of New York, reported data from a Phase IV study showed that Toviaz (fesoterodine fumarate) 8 mg once daily reduced urge urinary incontinence episodes in patients with overactive bladder per 24 hours from baseline to week 12, which was statistically significantly more than Toviaz 4 mg
Pharma: Clinic Roundup
Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, disclosed data from a Phase III study testing Eliquis (apixaban) for the prevention of recurrent venous thromboembolism (VTE
Clinic Roundup
Portola Pharmaceuticals Inc., of South San Francisco, said it started a Phase II study testing the safety and effectiveness of PRT4445, its universal antidote for Factor Xa inhibitor anticoagulants, in healthy volunteers who have been given approved and investigational Factor Xa inhibitors, including the oral drug Eliquis (apixaban, Bristol-Myers Squibb Co. and Pfizer Inc.) and Portola's own betrixaban...The pivotal study, designated ESTABLISH 2, is designed to examine the efficacy and safety of a
Pharma: Clinic Roundup
Pfizer Inc., of New York, said randomized Phase II data showed that PD-0332991 in combination with letrozole significantly extended progression-free survival (PFS) compared to letrozole alone in postmenopausal women with estrogen receptor-positive human epidermal growth factor receptor-1-negative locally advanced or metastatic breast cancer
Clinic Roundup
Intellipharmaceutics International Inc., of Toronto, reported results from an initial Phase I study showing that its controlled-release pregabalin formulation, given once daily, was comparable in bioavailability to Lyrica (pregabalin, Pfizer Inc.), administered three times daily
Pharma: Clinic Roundup
Pfizer Inc., of New York, said top-line data from a Phase III study testing pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicated that the product had a statistically significant positive effect compared to placebo in the primary endpoint, defined as time to loss of therapeutic response